Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC MOST POPULAR Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... May 2, 2022 Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung... June 23, 2020 Load more HOT NEWS Investment Needed to Bring Down Pancreatic Cancer Death Rates in Europe.... Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for...
